We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 3.03% | 17.00 | 16.50 | 17.50 | 17.00 | 16.50 | 16.50 | 87,304 | 16:04:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 644k | -2.04M | -0.0208 | -8.17 | 16.16M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/3/2019 16:31 | Rayrac. Your constant negative posting against this company must be giving you tension headaches. Please may I recommend you invest in a pot of tiger balm. To save You looking up the ingredients. It contains 60% real tiger. Highly recommended By Ruth Langford | jamesrs1 | |
15/3/2019 16:28 | This must be a frustrating share to hold! You guys need to calm down a bit...well a lot actually, and remember, never fall in love with a share...they are for trading! ;)) | rayrac | |
15/3/2019 15:58 | Rayrac, re. India, could you please answer my question regarding the number of Life Sciences companies signing multi-million pound deals? I refer you to my post below. So now that you are the self-proclaimed most knowledgeable poster on all things OPTI, could you point me to where it says "there were an awful lot of other life sciences companies represented there" and who were these companies? As you seem to have far too much time on your hands, it shouldn't be too difficult for you. Thanks. After New Delhi the Minister visited Mumbai where he met young entrepreneurs at the ‘Fintegrate Zone’ conference to further the UK’s position as a world leader in FinTech and position the UK as India’s partner of choice in raising finance. Among other engagements in Mumbai, he attended a multi-million pound UK-India life sciences deal signing; promoted UK-India sports links in the run up to the 2019 Cricket World Cup; and interacted with Indian youth leaders and Chevening alumni. | dire cons | |
15/3/2019 15:53 | Lol. Raywhack is used to being scammed. He now thinks product endorments by celebs having their name hijacked are real. Stupid stupid boy. A clear benchmark for his stupidness. | slartybartfaster | |
15/3/2019 15:24 | Even funnier is when you actually google the product. First thing that comes up:'Can someone let Ruth Langford know there is an ad online selling keto diet pills in her name and plenty of other celebs being used in same ad on her behalf...it's a scam!!' | riskybusiness1 | |
15/3/2019 15:15 | https://www.healthli | riskybusiness1 | |
15/3/2019 14:42 | Just got posted this from another almost lookalike.. Ruth Langsford, 58, is no stranger to the spotlight. With multiple hosting jobs and her work with QVC, she seems to be everywhere at once. But all of those projects are about to come to a halt as Ruth prepares to take a sharp turn in her career. "I love hosting Loose Women and This Morning. But it's time to change direction and take on my new business full time, so that it can reach its maximum potential." She said that although the decision wasn't easy, she knows it was the right choice. The new business project Ruth is referring to is her up and coming diet line Pure Keto Premium. The popular television personality has spent the past two years developing a line of highly potent and effective diet and wellness products that she claims are the solution for those who don’t want to resort to plastic surgery, expensive meal plans, or endless hours in the gym. Ruth explains the model behind her product. "The modern woman simply doesn't have the resources, be it time, money, or both, to maintain the figure she had in her twenties or thirties. But now with Pure Keto Premium, there's an easy way to lose weight without having to make lifestyle adjustments!" | rayrac | |
15/3/2019 14:41 | Don't worry old man. You just concern yourself with BPC 1.6p placing when the share price was 4p. All your ramping with Gizmo etal. You should be ashamed Raywhack. | slartybartfaster | |
15/3/2019 14:16 | Agree it is long, probably the biggest short term drawback to the model. If you think of it, these license deals involve using Optis technology to create, brand, market & launch their own product from scratch containing LPLDL rather than buying product from Opti. The bigger they are the more investment & time they will take bringing it to market making sure they make the eventual launch a success. Once these building blocks collectively come online revenue & growth will rapidly snowball. I believe we're holding strong in the 80's because the market can now visibly see this all coming together now on a £1.6m burn spread across 3 core businesses. Just need something substantial to fire us through £1 for good.TATA have been working on slimbiome for years so with ZEON to manufacture & supply in that market now, as soon as slimbiome becomes registered by Zeon to sell in India TATA should be ready to go. Have no idea how it works in that market but surely shouldn't take too long to get product registration. | riskybusiness1 | |
15/3/2019 14:06 | Buy sell ratio doesnt look good, and some bod/bods keep off loading 10k shares. I know it concerns judijudi, and I don’t blame her! India must be a bother too, especially after all the ramping of how big it was! | rayrac | |
15/3/2019 13:30 | Thanks Risky. That is a long lead in time for Alfasigma from the point of signing. I guess the biggger the company the longer it takes. Hope it’s quicker in India when we get Tata et al news. | imnotlong | |
15/3/2019 12:36 | Raywhack, id worry about your olies if i were you instead of getting stressed over Opti. I see BPC & UKOG are doing fine for you...NOT! I notice you and your ramping crew pumped BPC up to 4p just in time for the 1.6p placing...well done you sir! | slartybartfaster | |
15/3/2019 12:19 | Another interesting point from the RNS is 'The agreement restricts HLH from promoting and/or making sales, or exporting products outside these territories'This basically means they've reigned HLH in so you will not be able buy that product in the UK anymore. Arguably this isn't great for the consumer because Cholbiome is a few quid more expensive but commercially it's an excellent decision to build Cholbiome sales that will have a much higher unit sale price & therefore profit margin for Opti in the U.K. market. | riskybusiness1 | |
15/3/2019 12:12 | I think they plan to launch end of year/early next however they will order this financial year in order to get themselves launch ready. A company like Alfa Sigma your talking tons so £200k-£400k each order a number of times per year. They are a major player & a fantastic partner to have... looking at the VSL brand, sales in excess of tens of millions is very achievable through them.SEED health are looking like they will significantly ramp up sales into Asia which will be massive & why they are only selling to existing customers until they change manufacturing to suit that particular climate. Per said the majority of revenues were coming from US which must mean SEED and that Probiotix Health is already self sustaining so the pharma development milestones adding to 7 figures will add on top very nicely. Looks good | riskybusiness1 | |
15/3/2019 12:11 | So what happened to the expected rns from the India trip?! More smoke and mirrors as usual. Still no contracts for cash, just agreements to try Opti products in a highly competitive market. Boombod being just one example. | rayrac | |
15/3/2019 11:37 | I know. It was in 2 of TWs bearcasts last year. | slartybartfaster | |
15/3/2019 11:31 | Risky, those figures look reasonable to me. Have you any thoughts when Alfasigma products in Italy will go on sale? That can’t be too far away. | imnotlong | |
15/3/2019 11:17 | Hi Risky, agree with your min figs, I read it as those figures are from Germany alone with the new countries being extra markets, hence additional income. | belgrano2 | |
15/3/2019 10:42 | Remember they were AB-Biotics distributor that dropped AB life ingredient & replaced it with LPLDL as soon as it became available. Now they want to extend the scope of the original agreement agreeing to double sales each year. They're pretty established business so £500k+ after this contract extension imo will be a realistic recurring figure from this one deal within the next few years. | riskybusiness1 | |
15/3/2019 10:34 | They were one of the first off the mark, always listed as a small company along with another 35 players, if the others emulate this performance we’ll be more than happy and SOH will be well short of the mark in company valuation. | belgrano2 | |
15/3/2019 10:17 | Regular seller around again today I reckon Silly Billy :) | judijudi | |
15/3/2019 10:01 | RAF Well said. Too much over analysis of every rns. If you take a step back the fundamentals are that there’s lots of deals being done, the partners especially the latter deals are key players in their markets and there are multiple strains and products so not reliant on one thing. There is just so much going on here I’m finding it hard to keep track. For example I can’t believe nothing’s being discussed re improving LGG yet it’s at the back of everyone’s mind as since then we’ve had so much news. The board are top drawer, costs are well managed and we have multiple strains in multiple countries in a sector that is the next step for healthcare and wellbeing. Whether hlh do £20k or £200k this year to me doesn’t matter if the rate of growth they are committing to is doubling each year then the product has traction and sales are only going one way as word spreads. So HLH have signed a deal doubling sales, seed are launching in further countries and continue to re order. The signs are there. | shrewdmole | |
15/3/2019 09:57 | Sounds about right TT, looking at comments from the original June 2017 rns, projections were mid to low 6 figs, so they have done well. | belgrano2 | |
15/3/2019 09:34 | I don't know about everyone else but this sort of announcement reassures me about the rapid ramping up of sales in the near future. Yes this is only one partner in one country and some are going to be better than others at achieving sale stargets but nevertheless this shows what is possible. As I may have said before, in my long investment experience this is the best company I have ever seen and anyone who can see beyond the end of their nose, should be able to realise this! | nobbygnome | |
15/3/2019 09:18 | I'd also add it is likely the £250k overall has been revised up on this deal after the 'doubling each year' clause. | riskybusiness1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions